2.10
0.12 (6.06%)
| 前收盘价格 | 1.98 |
| 收盘价格 | 1.98 |
| 成交量 | 50,829 |
| 平均成交量 (3个月) | 402,927 |
| 市值 | 97,206,056 |
| 价格/销量 (P/S) | 2.13 |
| 股市价格/股市净资产 (P/B) | 1.33 |
| 52周波幅 | |
| 利润日期 | 19 Mar 2025 |
| 营业毛利率 | -246.06% |
| 营业利益率 (TTM) | -149.40% |
| 稀释每股收益 (EPS TTM) | -2.28 |
| 季度收入增长率 (YOY) | 21.00% |
| 总债务/股东权益 (D/E MRQ) | 1.37% |
| 流动比率 (MRQ) | 4.89 |
| 营业现金流 (OCF TTM) | -54.14 M |
| 杠杆自由现金流 (LFCF TTM) | -35.62 M |
| 资产报酬率 (ROA TTM) | -35.27% |
| 股东权益报酬率 (ROE TTM) | -65.95% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Aadi Bioscience, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | -0.38 |
|
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.10% |
| 机构持股比例 | 50.02% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合